These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 8787239)

  • 21. Clinical trials in amyotrophic lateral sclerosis: the tenuous past and the promising future.
    Choudry RB; Cudkowicz ME
    J Clin Pharmacol; 2005 Dec; 45(12):1334-44. PubMed ID: 16291708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design of phase II ALS clinical trials.
    Schoenfeld DA; Cudkowicz M
    Amyotroph Lateral Scler; 2008; 9(1):16-23. PubMed ID: 18273715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical development of levetiracetam for amyotrophic lateral sclerosis.
    Davies SL; Moral MA
    Drug News Perspect; 2006 Nov; 19(9):572-3. PubMed ID: 17220961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Collaborative National ALS Study Group. Patient orientated research and clinical trials.
    Bradley WG
    J Neurol Sci; 2006 Mar; 242(1-2):71-4. PubMed ID: 16386274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of amyotrophic lateral sclerosis - what is the next step?
    Ludolph AC
    J Neurol; 2000 Dec; 247 Suppl 6():VI/13-8. PubMed ID: 19714403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Riluzole in amyotrophic lateral sclerosis.
    Murphy JR
    N Engl J Med; 1994 Jul; 331(4):273; author reply 273-4. PubMed ID: 8015580
    [No Abstract]   [Full Text] [Related]  

  • 27. Therapy development for ALS: lessons learned and path forward.
    Lanka V; Cudkowicz M
    Amyotroph Lateral Scler; 2008 Jun; 9(3):131-40. PubMed ID: 18574756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An efficient multi-stage, single-arm Phase II futility design for ALS.
    Palesch YY; Tilley BC
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():55-6. PubMed ID: 15512874
    [No Abstract]   [Full Text] [Related]  

  • 29. Regulatory issues in ALS clinical trials.
    Bryan WW
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():36-41. PubMed ID: 15512868
    [No Abstract]   [Full Text] [Related]  

  • 30. Enhancing clinical trials in neurodegenerative disorders: lessons from amyotrophic lateral sclerosis.
    Gladman M; Cudkowicz M; Zinman L
    Curr Opin Neurol; 2012 Dec; 25(6):735-42. PubMed ID: 23160423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The value of database controls in pilot or futility studies in ALS.
    Czaplinski A; Haverkamp LJ; Yen AA; Simpson EP; Lai EC; Appel SH
    Neurology; 2006 Nov; 67(10):1827-32. PubMed ID: 17130417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multi-drug therapy in amyotrophic lateral sclerosis: combinations of multiple, untested drugs should not be used at this time.
    Shefner JM
    Muscle Nerve; 2004 Nov; 30(5):676-8. PubMed ID: 15452839
    [No Abstract]   [Full Text] [Related]  

  • 33. ALS issues in clinical trials. Missing data.
    Thompson JL; Levy G
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():48-51. PubMed ID: 15512872
    [No Abstract]   [Full Text] [Related]  

  • 34. Randomized control trials in ALS: lessons learned.
    Mitsumoto H; Gordon P; Kaufmann P; Gooch CL; Przedborski S; Rowland LP
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():8-13. PubMed ID: 15512861
    [No Abstract]   [Full Text] [Related]  

  • 35. Scrutinizing enrollment in ALS clinical trials: room for improvement?
    Bedlack RS; Pastula DM; Welsh E; Pulley D; Cudkowicz ME
    Amyotroph Lateral Scler; 2008 Oct; 9(5):257-65. PubMed ID: 18608092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies.
    Bruijn LI; Cudkowicz M
    Expert Rev Neurother; 2006 Mar; 6(3):417-28. PubMed ID: 16533145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Update on fundamental and clinical research in amyotrophic lateral sclerosis].
    Pradat PF; Camdessanché JP; Carluer L; Cintas P; Corcia P; Danel-Brunaud V; Echaniz-Laguna A; Gonzalez J; Nicolas G; Vandenberghe N; Verschueren A;
    Rev Neurol (Paris); 2009; 165(6-7):532-41. PubMed ID: 19419744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Possible etiological role retroviruses and enteroviruses in the development of amyotrophic lateral sclerosis].
    Portegies P; Cohen ES
    Ned Tijdschr Geneeskd; 2002 Jul; 146(30):1398-400. PubMed ID: 12174431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Controversies about amyotrophic lateral sclerosis.
    Rowland LP
    Neurologia; 1996 Dec; 11 Suppl 5():72-4. PubMed ID: 9011143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroprotective agents for clinical trials in ALS: a systematic assessment.
    Traynor BJ; Bruijn L; Conwit R; Beal F; O'Neill G; Fagan SC; Cudkowicz ME
    Neurology; 2006 Jul; 67(1):20-7. PubMed ID: 16832072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.